Akums Drugs & Pharma IPO: Public Issue Subscribed 3x On Day 2, GMP Hints Strong Listing; Key Details

The Akums Drugs and Pharmaceuticals Initial Public Offering (IPO) has captured the attention of investors. The IPO, which opened for subscription on July 30 and will close on August 1, saw an overwhelming response right from the get-go. Within just an hour of opening, the retail segment was fully subscribed.

Akums Drugs and Pharmaceuticals, a pharmaceutical contract development and manufacturing organization (CDMO) established in 2004, offers a wide array of pharmaceutical products and services both domestically and internationally. Their IPO, worth Rs 1,857 crore, includes a fresh issue of Rs 680 crore and an offer-for-sale (OFS) of 17,330,435 equity shares by the promoters and other investors.

As of 1:27 pm on the second day of bidding, the IPO subscription status stood at an impressive 2.73 times. The retail investor portion had garnered 6.65 times subscription, while non-institutional investors (NIIs) showed significant interest with a 4.74 times subscription rate. Qualified Institutional Buyers (QIBs), who make up 44% of the total buyers, subscribed 1.84 times. This level of interest underscores the strong market confidence in Akums' growth potential.

The IPO has a price band set between Rs 646 and Rs 679 per share. Investors can bid for a minimum of 22 equity shares and in multiples thereafter. To further bolster confidence, the company raised Rs 829 crore from anchor investors just before the public subscription period began, indicating strong institutional backing.

Akums has allocated 75% of the issue size for QIBs, 15% for NIIs, and the remaining 10% for retail investors.

The proceeds from the IPO are earmarked for several strategic purposes. The fresh issue will be utilized to pay off the company's and its subsidiaries debts, which include Pure and Cure Healthcare, Maxcure Nutravedics, and Pure. Additionally, funds will be allocated for inorganic growth projects and to meet increased working capital needs.

The OFS component involves offloading by Ruby QC Investment Holdings Pte Ltd, which will sell 1.43 crore shares, and the promoters, Sanjeev and Sandeep Jain, each selling 15.12 lakh equity shares. This move will provide liquidity to the investors while also reflecting the promoters' strategy to diversify ownership and invite new strategic investors.

The Akums Drugs IPO has generated considerable buzz in the grey market, with a premium of +177, indicating robust investor confidence. This premium suggests that shares are trading at Rs 177 above the issue price in unofficial markets, projecting an estimated listing price of Rs 856 apiece. This represents a 26.07% increase over the upper end of the IPO price band, a clear indicator of the market's bullish sentiment towards the company.

The book-running lead managers for this IPO include heavyweights such as ICICI Securities Ltd, Axis Bank Ltd, Citigroup Global Markets India Private Ltd, and Ambit Private Ltd. The registrar for the offering is Link Intime India Private Ltd.

The overwhelming response to the Akums Drugs IPO reflects not only the market's confidence in the company's robust business model but also its optimistic outlook on the pharmaceutical sector. As Akums continues to expand its footprint, both domestically and internationally, the funds raised will be pivotal in scaling operations, enhancing R&D capabilities, and pursuing strategic acquisitions.

In the broader context, the bullish trends in the Nifty 50, coupled with investor enthusiasm for Akums, reflect a favourable economic environment. As the market eyes the 25,000 mark, investments in strong, growth-oriented companies like Akums Drugs and Pharmaceuticals are seen as prudent moves.

The successful subscription of Akums Drugs IPO amid a bullish market phase highlights the strategic timing and strong market positioning of the company. With substantial funds raised, strategic debt reduction plans, and a clear path for growth, Akums is well-poised to capitalize on favourable market conditions.